Shares of EndoChoice Holdings Inc. (NYSE:GI) have received an average broker rating score of 2.75 (Hold) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a strong buy rating on the company. EndoChoice Holdings’ rating score has declined by 57.1% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 1 year consensus price target of $7.50 for the company and are anticipating that the company will post ($0.52) EPS for the current quarter, according to Zacks. Zacks has also assigned EndoChoice Holdings an industry rank of 161 out of 265 based on the ratings given to related companies.
Several analysts have recently commented on the stock. Stifel Nicolaus lowered their target price on shares of EndoChoice Holdings from $10.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, August 4th. William Blair reiterated a “market perform” rating on shares of EndoChoice Holdings in a report on Friday, September 30th. JPMorgan Chase & Co. assumed coverage on shares of EndoChoice Holdings in a report on Wednesday, July 13th. They issued an “overweight” rating for the company. Finally, Zacks Investment Research upgraded shares of EndoChoice Holdings from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Tuesday, July 5th.
Shares of EndoChoice Holdings (NYSE:GI) opened at 7.98 on Friday. The firm’s market cap is $207.86 million. The firm has a 50-day moving average of $5.13 and a 200 day moving average of $4.87. EndoChoice Holdings has a 52 week low of $3.64 and a 52 week high of $12.44.
EndoChoice Holdings (NYSE:GI) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.99) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.47. EndoChoice Holdings had a negative return on equity of 62.04% and a negative net margin of 88.94%. The business had revenue of $19.30 million for the quarter, compared to analyst estimates of $20.67 million. During the same quarter in the previous year, the company posted ($1.01) EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. Equities research analysts predict that EndoChoice Holdings will post ($2.53) EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the stock. Iguana Healthcare Management LLC raised its position in EndoChoice Holdings by 8.7% in the second quarter. Iguana Healthcare Management LLC now owns 125,000 shares of the company’s stock valued at $613,000 after buying an additional 10,000 shares during the last quarter. State Street Corp raised its position in EndoChoice Holdings by 46.7% in the first quarter. State Street Corp now owns 76,915 shares of the company’s stock valued at $402,000 after buying an additional 24,500 shares during the last quarter. Paloma Partners Management Co bought a new position in EndoChoice Holdings during the second quarter valued at $161,000. Vanguard Group Inc. raised its position in EndoChoice Holdings by 13.8% in the second quarter. Vanguard Group Inc. now owns 274,967 shares of the company’s stock valued at $1,348,000 after buying an additional 33,427 shares during the last quarter. Finally, Emerald Acquisition Ltd. bought a new position in EndoChoice Holdings during the second quarter valued at $215,000. Institutional investors own 37.71% of the company’s stock.
EndoChoice Holdings Company Profile
EndoChoice Holdings, Inc is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EndoChoice Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EndoChoice Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.